ValuentumAd

Official PayPal Seal













Fundamental data is updated weekly, as of the prior weekend. Please download the Full Report and Dividend Report for any changes.
Aug 31, 2018
Stellar Keytruda Growth Powers Merck Higher
Shares of pharmaceutical giant Merck continue to accelerate thanks in large part to the growth of its key oncology asset Keytruda. Even though Merck is a well-established entity, future growth is highly correlated to the continued expansion of Keytruda as it continues to gain market share thanks in large part to superior clinical data and label expansion.
Aug 31, 2018
Dividend Increases/Decreases for the Week Ending August 31
Let's take a look at companies that raised/lowered their dividend this week.
Aug 29, 2018
Intel Unveils Plans to Take on Heightened Competition
Image Source: Intel analyst presentation. Shares of simulated newsletter portfolios idea Intel have faced material selling pressure in mid-2018 as a result of a number of reports of increased competition from rivals, namely AMD. We're not worried and still like the company's valuation profile.
Aug 24, 2018
The Days of the MLP Model Are Numbered
We applaud Enbridge-Spectra on explaining the MLP business model with transparency. Though we think rollups could bring new capital into the MLP space, we expect the days of the MLP model are numbered. The opportunity to raise capital at yield-based pricing has been eliminated.
Aug 24, 2018
Dividend Increases/Decreases for the Week Ending August 24
Let's take a look at companies that raised/lowered their dividend this week.
Aug 23, 2018
In the News: Pot, Pop, and Pricing Wars
Let’s take a look at some of the hottest topics around the markets.
Aug 23, 2018
Honeywell Remains a Top Industrial Idea
Image Source: Honeywell. Honeywell continues to perform fantastically, and the company raised its full-year bottom-line guidance for 2018. It boasts a strong Dividend Cushion ratio supported by tremendous free cash flow generation. The company's planned spinoffs remain on track.
Aug 23, 2018
Pfizer: Lots of Moving Parts in a Generally-Inspiring Second Quarter
Image Source: Pfizer. We came away generally impressed with the progress at Pfizer during the second quarter as the company begins to replace its current patent protected line-up with next-generation treatments. Pfizer continues to gain political favor with its decision to forgo price hikes on its product line-up while announcing a re-organization of the business structure.
Aug 22, 2018
EOG Resources "Firing On All Cylinders"
EOG Resources is back on track, and we like it. We value shares slightly lower than where the market does, but we could see upside on the basis of the high end of our fair value estimate range. The company's equity is not without substantial operational and financial risk, however. Debt can come back to hurt shares during weak economic times.
Aug 22, 2018
General Electric: The Quintessential Falling Knife
General Electric is a great example showcasing why it is so important to avoid falling knives. We value shares at about $20 each, but we would only grow interested in them if the share price starts to move meaningfully higher. Without the backing of the market as evidenced by a rising share price, it may be too early to say the worst is over at GE.


The High Yield Dividend Newsletter, Best Ideas Newsletter, Dividend Growth Newsletter, Nelson Exclusive publication, and any reports, articles and content found on this website are for information purposes only and should not be considered a solicitation to buy or sell any security. The sources of the data used on this website are believed by Valuentum to be reliable, but the data’s accuracy, completeness or interpretation cannot be guaranteed. Valuentum is not responsible for any errors or omissions or for results obtained from the use of its newsletters, reports, commentary, or publications and accepts no liability for how readers may choose to utilize the content. Valuentum is not a money manager, is not a registered investment advisor and does not offer brokerage or investment banking services. Valuentum, its employees, and affiliates may have long, short or derivative positions in the stock or stocks mentioned on this site.